Navigation Links
ISTA Pharmaceuticals Announces 2010 Financial Guidance
Date:2/9/2010

p>

About ISTA Pharmaceuticals

ISTA Pharmaceuticals is the fourth largest branded ophthalmic pharmaceutical business in the U.S. ISTA's four marketed products plus its product candidates include therapies for inflammation, ocular pain, allergy, glaucoma, and dry eye. The Company is developing a strong product pipeline to fuel future growth and market share, supporting its goal to become the leading niche ophthalmic pharmaceutical company in the U.S. For additional information regarding ISTA, please visit ISTA Pharmaceuticals' website at http://www.istavision.com/.  

Forward-looking Statements

Any statements contained in this press release that refer to future events or other non-historical matters are forward-looking statements. Without limiting the foregoing, but by way of example, statements contained in this press release relating to ISTA's 2010 expected financial results, ISTA's expectation to begin a Phase 3 study for ISTA's new formulation of bromfenac in 2010 and complete the formulation of bepotastine nasal and initiate full-scale clinical development during the year are forward-looking statements. Except as required by law, ISTA disclaims any intent or obligation to update any forward-looking statements. These forward-looking statements are based on ISTA's expectations as of the date of this press release and are subject to risks and uncertainties that could cause actual results to differ materially. Important factors that could cause actual results to differ from current expectations include, among others: timely and successful implementation of ISTA's strategic initiatives; delays and uncertainties related to ISTA's research and development programs (including the difficulty o
'/>"/>

SOURCE ISTA Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... , July 28, 2015 ... new research report with market overview, trends, ... forecast, porter analysis, recent developments, competitive scenario ... Global Industry Insight: Human Insulin Market Development ...      (Logo: http://photos.prnewswire.com/prnh/20150727/756778) Explore more ...
(Date:7/28/2015)...  Roche (SIX: RO, ROG; OTCQX: RHHBY) launched ... Chemistry (AACC) 2015 Clinical Lab Expo today by ... unique educational initiative that demonstrates how Roche is ... the laboratory. The new LabLeaders initiative ... and the people within them through insight from ...
(Date:7/28/2015)... LINCOLNSHIRE, Ill. , July 28, 2015 ... leverage business acumen on par with their levels of ... Clinical Chemistry (AACC) Annual Meeting & Clinical Lab Expo, ... Box™ to deliver a comprehensive and intuitive ecosystem that ... advances in four key areas, Sysmex aims to add ...
Breaking Medicine Technology:Global Human Insulin Market (Size of $24 billion in 2014) to Witness 13% CAGR During 2015 - 2020 2Global Human Insulin Market (Size of $24 billion in 2014) to Witness 13% CAGR During 2015 - 2020 3Global Human Insulin Market (Size of $24 billion in 2014) to Witness 13% CAGR During 2015 - 2020 4Global Human Insulin Market (Size of $24 billion in 2014) to Witness 13% CAGR During 2015 - 2020 5Roche introduces LabLeaders educational initiative to help redefine the value of the laboratory at AACC 2015 Clinical Lab Expo 2Roche introduces LabLeaders educational initiative to help redefine the value of the laboratory at AACC 2015 Clinical Lab Expo 3Roche introduces LabLeaders educational initiative to help redefine the value of the laboratory at AACC 2015 Clinical Lab Expo 4Sysmex Moves Beyond a Better Box 2Sysmex Moves Beyond a Better Box 3Sysmex Moves Beyond a Better Box 4
... Expand Testing Using Cellular ... Antioxidant Activity Assay, ... with the release of results from a new study,showing Wild ... red grapes and strawberries in an expanded,test using the Cellular ...
... Oct. 8 Vical Incorporated (Nasdaq: VICL ... nonclinical data,demonstrating that the company,s Vaxfectin(R) adjuvant may ... vaccines and,peptide-based cancer vaccines. Alain P. Rolland, Pharm.D., ... present the data today,Wednesday, October 8, at the ...
Cached Medicine Technology:Wild Blueberries Take Top Spot in New Antioxidant Research Study 2Wild Blueberries Take Top Spot in New Antioxidant Research Study 3Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 2Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 3Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 4Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 5
(Date:7/28/2015)... ... July 28, 2015 , ... ADLINK Technology, a leading ... devices that enable the Internet of Things (IoT), announced its new medical panel ... provide exceptional computing power and multitasking capabilities. The MLC 4-21 is completely fanless, ...
(Date:7/28/2015)... ... July 28, 2015 , ... OrthAlign, Inc., ... its ORTHALIGN PLUS® system, a palm-sized, single-use navigation device for Total Hip Arthroplasty ... precision with practicality in a revolutionary way for Total Knee Arthroplasty surgeries and ...
(Date:7/28/2015)... ... July 28, 2015 , ... On July 16th ... to schedule the hearing of proposed bills and laws revolving the implementation of a ... to date. Some vigilante ministers are continuing to hand out clean needles to drug ...
(Date:7/28/2015)... ... July 28, 2015 , ... BiologicsMD, Inc. , a ... the treatment of bone disorders and conditions of hair loss, announced that the ... of Collagen Binding-Domain and Parathyroid Hormone". The issued patent claims methods of use ...
(Date:7/28/2015)... ... ... Fertility specialist Dr. Lisa Hasty of Atlanta Center for Reproductive ... Atlanta Magazine's annual Top Doctors issue, Dr. Hasty has been recognized for the fifth ... metro area as one of the most respected doctors in Reproductive Endocrinology. , “I’m ...
Breaking Medicine News(10 mins):Health News:ADLINK Launches High Performance, Fully-Sealed Medical-Grade Panel PC 2Health News:ADLINK Launches High Performance, Fully-Sealed Medical-Grade Panel PC 3Health News:OrthAlign, Inc. Announces U.S. Commercial Launch of ORTHALIGN PLUS®, the most complete handheld navigation device for use in Total Hip Arthroplasty Surgery 2Health News:OrthAlign, Inc. Announces U.S. Commercial Launch of ORTHALIGN PLUS®, the most complete handheld navigation device for use in Total Hip Arthroplasty Surgery 3Health News:Needle Exchange Programs Are Delayed in Legislation, West Palm Beach Drug Rehab Comments 2Health News:Needle Exchange Programs Are Delayed in Legislation, West Palm Beach Drug Rehab Comments 3Health News:BiologicsMD, Inc. Announces Additional US Patent Issuance Covering Company’s Pipeline of Targeted Therapies 2Health News:Atlanta Fertility Specialist Named Top Doctor in Atlanta Magazine 2Health News:Atlanta Fertility Specialist Named Top Doctor in Atlanta Magazine 3
... shorts in football prints and innerwear with net inserts ... lingerie designers are experimenting with.,Overall, the trend in lingerie ... with a hint of romance. The seductive undergarments require ... being tried with embroidery. The garments aren't so opulent, ...
... 7,000 cancer tumour samples for researchers all over the world ... the world over are hailing this step as a major ... truly international. ,"Cancer is not just one disease, ... misbehaving. Since it is multiple diseases, you have to have ...
... death has been reported in Egypt, the most populous North ... woman //, indeed died as a consequence of the highly ... from Nawa village in Qalyubiya, some 40 km north of ... she had been treated for flu-like symptoms, the health ministry ...
... the avian influenza H5N1 virus is receiving samples from across ... arrive each week, packed in ice boxes. // These samples ... chicken deaths and from routine surveillance sites. , ... Animal Disease Laboratory in Bhopal, is running out of space ...
... in kidney transplant recipients can be used in treatment ... 40 years ago, is still used to prevent the ... ,In around the 1960s, Roy Calne showed that ... this finding, a combination of azathioprine and corticosteroids were ...
... the direction of development of prosthetic limbs researchers at University ... by alcohol and hydrogen. // ,As it appears ... than the body's own. ,Two types of ... Institute at the University of Texas in Dallas, working with ...
Cached Medicine News:Health News:Romantic and discreet trends in lingerie 2Health News:Azathioprine Can Soon Revolutionize Eczema Treatment 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: